Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

Trial ID # NCT02766582
Phase II
Drug Class Immunotherapy: Checkpoint Inhibitors/PD-1
Drug Name Pembrolizumab
Alternate Drug Names Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475
Drugs in Trial Carboplatin, Paclitaxel, Pembrolizumab
Eligible Participant

Stage III–IV epithelial ovarian cancer with residual disease after cytoreductive surgery

Patients Enrolled


Therapy Setting


Study Design

Open-Label, Non-randomized


PFS, evaluated per RECIST


PFS (6 months): 82%
PFS (9 months): 77%
PFS (12 months): 59%

Clinically Significant Adverse Events

Serious AE:
Grade 3-4 AE: neutropenia (67%), anemia (25%), respiratory (10%)


Pembrolizumab with carboplatin+paclitaxel on a weekly schedule is overall well tolerated and 12 months PFS is promising


Uyar D et al. Preliminary results from phase II trial of pembrolizumab with first line platinum based chemotherapy followed by maintenance pembrolizumab for patients with suboptimally cytoreduced advanced epithelial ovarian cancer. SGO (2020) abstract 314

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.